Agonizing Over Treg Expansion to Treat Human Disease: An Update on Our TNFRSF25-Agonist, PTX-35
Time: 4:30 pm
day: Day One | Track B | Afternoon
Details:
- Describing a clinical-stage Treg immunomodulator with utility in both oncology and auto/inflammation
- Demonstrating preclinical efficacy in several indications including transplantation, autoimmunity, and metabolic diseases
- Expanding plans for new indications & modalities – opportunities for partnerships
